Peptide Research
GLP-1 Discontinuation and Weight Regain: What Published Trials Show
⚠ FOR EDUCATIONAL AND SCIENTIFIC REFERENCE PURPOSES ONLY. THIS ARTICLE SUMMARISES PUBLISHED CLINICAL LITERATURE AND IS NOT MEDICAL ADVICE.
Quick answer: Randomised withdrawal trials consistently report substantial weight regain after GLP-1 receptor agonist discontinuation. In the STEP-1 extension, participants regained a...
THE BIG PEPTIDE SHIFT: WHAT’S CHANGING, WHAT TO EXPECT, AND WHAT IT MEANS FOR YOU
THE BIG PEPTIDE SHIFT: WHAT'S CHANGING, WHAT TO EXPECT, AND WHAT IT MEANS FOR YOU
14 Peptides May Return to Legal Compounding. Here's Everything You Need to Know — In Plain English.
FOR RESEARCH AND EDUCATIONAL PURPOSES ONLY
This document provides educational information about emerging peptide compounding regulations and...
WHY DID PEPTIDE SCIENCES SHUT DOWN OVERNIGHT?
WHY DID PEPTIDE SCIENCES SHUT DOWN OVERNIGHT?
The inside story: FDA enforcement, pharmaceutical litigation, and the quality failures behind a $7.4M/month closure
Quick answer: Peptide Sciences, the largest U.S. gray-market research peptide vendor, shut down abruptly in March 2026 amid FDA scrutiny and pharmaceutica...
PATH TO PEPTIDES GLP-1 AND SLEEP APNEA
PATH TO PEPTIDES GLP-1 AND SLEEP APNEA:
BREATHE EASIER, SLEEP BETTER
Tirzepatide became the first-ever medication approved for obstructive sleep apnea.
THE FIRST GLP-1 SLEEP APNEA DRUG — EVER
Quick answer: Tirzepatide became the first medication ever approved for obstructive sleep apnea, offering a new treatment ...
PATH TO PEPTIDES GLP-1 AND YOUR LIVER
PATH TO PEPTIDES GLP-1 AND YOUR LIVER:
THE MASH BREAKTHROUGH
Fatty liver disease affects 1 in 3 adults. Semaglutide just became the first GLP-1 approved to treat it.
THE SILENT GLP-1 FATTY LIVER EPIDEMIC
Quick answer: Semaglutide became the first GLP-1 medication approved to treat MASH (metabolic dysfunction-asso...
PATH TO PEPTIDES GLP-1 AND YOUR KIDNEYS
PATH TO PEPTIDES GLP-1 AND YOUR KIDNEYS:
THE FLOW TRIAL BREAKTHROUGH
Semaglutide now FDA-approved to protect kidneys. Here's what the science says.
GLP-1 KIDNEY PROTECTION: A FOURTH PILLAR
Quick answer: The FDA approved semaglutide in January 2025 to reduce the risk of kidney disease progression, based on the FLO...
PATH TO PEPTIDES THE GLP-1 PILL IS HERE
PATH TO PEPTIDES THE GLP-1 PILL IS HERE:
NO MORE NEEDLES?
Oral Wegovy just got FDA-approved. Orforglipron is next. Welcome to the pill era.
THE GLP-1 PILL AND THE END OF THE NEEDLE ERA
Quick answer: The FDA approved oral Wegovy in December 2025, marking the first pill-form GLP-1 medication, with orforglipron expe...
Antimicrobial Peptides (AMPs) in Research: Mechanisms and Pipeline
⚠ FOR LABORATORY RESEARCH AND EDUCATIONAL PURPOSES ONLY — NOT FOR HUMAN OR ANIMAL CONSUMPTION.
Quick answer: Antimicrobial peptides (AMPs), also called host-defense peptides, are short peptides that many organisms produce as part of innate immunity against bacteria, viruses, and fungi. Because they disrupt microbial memb...
Collagen Peptide Research: Pro-Hyp, GHK-Cu and Matrix Pathways
⚠ FOR LABORATORY RESEARCH AND EDUCATIONAL PURPOSES ONLY — NOT FOR HUMAN OR ANIMAL CONSUMPTION.
Quick answer: Collagen peptide research covers two distinct areas that are often confused. The first is dietary hydrolysed collagen, where studies have examined whether specific fragments such as Pro-Hyp survive digestion. The ...
GLP-1 Weight Loss and Body Composition: What Research Shows About Lean Mass
⚠ FOR EDUCATIONAL AND SCIENTIFIC REFERENCE PURPOSES ONLY. THIS ARTICLE SUMMARISES PUBLISHED CLINICAL LITERATURE AND IS NOT MEDICAL ADVICE.
Quick answer: Body composition studies report that lean soft tissue accounts for roughly 20–40% of total weight reduction during GLP-1 receptor agonist treatment, measured by DXA. How...